Myriad Genetics Inc
MYGN3.980USD
+0.070+1.79%
Fechamento 08/04, 16:00（ET）Cotações atrasadas em 15 min
366.96MValor de mercado
PerdaP/L TTM
Mais detalhes de Myriad Genetics Inc Empresa
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight, among others.
Informações da empresa
Código da empresaMYGN
Nome da EmpresaMyriad Genetics Inc
Data de listagemOct 06, 1995
CEOMr. Samraat S. (Sam) Raha
Número de funcionários2700
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 06
Endereço322 North 2200 West
CidadeSALT LAKE CITY
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal84116
Telefone18015843600
Sitehttps://myriad.com/
Código da empresaMYGN
Data de listagemOct 06, 1995
CEOMr. Samraat S. (Sam) Raha
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Brian Donnelly
Mr. Brian Donnelly
Chief Commercial Officer
Chief Commercial Officer
397.53K
--
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer and Chief Commercial Officer
Chief Operating Officer and Chief Commercial Officer
221.65K
-11.52%
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
132.14K
+60.47%
Ms. Margaret (Maggie) Ancona
Ms. Margaret (Maggie) Ancona
Senior Vice President, Chief of Staff
Senior Vice President, Chief of Staff
128.68K
+56.61%
Ms. Rashmi Kumar
Ms. Rashmi Kumar
Independent Director
Independent Director
127.19K
+64.34%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
110.96K
+98.89%
Dr. Dale Muzzey
Dr. Dale Muzzey
Chief Scientific Officer
Chief Scientific Officer
45.88K
-46.96%
Ms. S. Louise Phanstiel, CPA
Ms. S. Louise Phanstiel, CPA
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Matt Scalo
Mr. Matt Scalo
Investor Relations
Investor Relations
--
--
Ms. Jennifer Fox
Ms. Jennifer Fox
Chief Legal Officer
Chief Legal Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Brian Donnelly
Mr. Brian Donnelly
Chief Commercial Officer
Chief Commercial Officer
397.53K
--
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer and Chief Commercial Officer
Chief Operating Officer and Chief Commercial Officer
221.65K
-11.52%
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
132.14K
+60.47%
Ms. Margaret (Maggie) Ancona
Ms. Margaret (Maggie) Ancona
Senior Vice President, Chief of Staff
Senior Vice President, Chief of Staff
128.68K
+56.61%
Ms. Rashmi Kumar
Ms. Rashmi Kumar
Independent Director
Independent Director
127.19K
+64.34%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
110.96K
+98.89%
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
Por EmpresaUSD
Nome
Receita
Proporção
Hereditary Cancer
86.30M
44.05%
Prenatal
49.30M
25.17%
Pharmacogenomics
31.00M
15.82%
Tumor Profiling
29.30M
14.96%
Por RegiãoUSD
Nome
Receita
Proporção
United States
181.60M
92.70%
Rest of world
14.30M
7.30%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Hereditary Cancer
86.30M
44.05%
Prenatal
49.30M
25.17%
Pharmacogenomics
31.00M
15.82%
Tumor Profiling
29.30M
14.96%
Distribuição de ações
Atualizado em: qui, 15 de mai
Atualizado em: qui, 15 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
15.02%
The Vanguard Group, Inc.
10.04%
State Street Global Advisors (US)
5.72%
Disciplined Growth Investors, Inc.
5.14%
Wellington Management Company, LLP
4.98%
Other
59.10%
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
15.02%
The Vanguard Group, Inc.
10.04%
State Street Global Advisors (US)
5.72%
Disciplined Growth Investors, Inc.
5.14%
Wellington Management Company, LLP
4.98%
Other
59.10%
Tipos de investidores
Investidores
Proporção
Investment Advisor
47.03%
Investment Advisor/Hedge Fund
31.99%
Hedge Fund
18.89%
Research Firm
3.85%
Individual Investor
3.25%
Pension Fund
1.35%
Bank and Trust
0.41%
Sovereign Wealth Fund
0.07%
Insurance Company
0.04%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
514
98.55M
106.92%
-3.88M
2025Q1
527
99.14M
107.57%
-4.54M
2024Q4
516
96.89M
106.12%
-1.41M
2024Q3
505
95.02M
104.61%
-5.50M
2024Q2
486
96.79M
106.52%
-6.22M
2024Q1
460
98.19M
108.68%
+613.48K
2023Q4
464
93.46M
105.77%
+2.70M
2023Q3
471
86.01M
104.78%
-3.73M
2023Q2
480
84.60M
103.32%
-6.34M
2023Q1
483
85.87M
105.37%
-2.69M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
BlackRock Institutional Trust Company, N.A.
13.85M
15.02%
-471.44K
-3.29%
Mar 31, 2025
The Vanguard Group, Inc.
10.62M
11.52%
+47.03K
+0.44%
Mar 31, 2025
State Street Global Advisors (US)
5.27M
5.72%
-256.92K
-4.65%
Mar 31, 2025
Disciplined Growth Investors, Inc.
4.73M
5.14%
+2.18M
+85.16%
Mar 31, 2025
Wellington Management Company, LLP
4.59M
4.98%
-1.41M
-23.52%
Mar 31, 2025
Millennium Management LLC
4.07M
4.41%
-275.67K
-6.34%
Mar 31, 2025
EARNEST Partners, LLC
3.98M
4.31%
+5.69K
+0.14%
Mar 31, 2025
Glenview Capital Management, LLC
3.90M
4.23%
-257.77K
-6.20%
Mar 31, 2025
D. E. Shaw & Co., L.P.
2.52M
2.74%
+702.80K
+38.62%
Mar 31, 2025
SEI Investments Management Corporation
2.42M
2.62%
-110.27K
-4.36%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Global X Genomics & Biotechnology ETF
0.6%
WisdomTree BioRevolution Fund
0.6%
Invesco NASDAQ Future Gen 200 ETF
0.57%
Invesco S&P SmallCap Health Care ETF
0.35%
Federated Hermes MDT Small Cap Core ETF
0.3%
Strategas Global Policy Opportunities ETF
0.21%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.18%
SPDR S&P Biotech ETF
0.15%
Inspire Small/Mid Cap ESG ETF
0.12%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.09%
Ver Mais
Global X Genomics & Biotechnology ETF
Proporção0.6%
WisdomTree BioRevolution Fund
Proporção0.6%
Invesco NASDAQ Future Gen 200 ETF
Proporção0.57%
Invesco S&P SmallCap Health Care ETF
Proporção0.35%
Federated Hermes MDT Small Cap Core ETF
Proporção0.3%
Strategas Global Policy Opportunities ETF
Proporção0.21%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proporção0.18%
SPDR S&P Biotech ETF
Proporção0.15%
Inspire Small/Mid Cap ESG ETF
Proporção0.12%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporção0.09%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
